Literature DB >> 21035737

Fluorescent probes of tissue transglutaminase reveal its association with arterial stiffening.

Nicolas Chabot1, Simon Moreau, Amina Mulani, Pierre Moreau, Jeffrey W Keillor.   

Abstract

Tissue transglutaminase (TG2) catalyzes the crosslinking of proteins. TG2 has been implicated in fibrosis and vascular calcification, both of which lead to a common feature of aging known as arterial stiffness. In order to probe the role of TG2 in arterial rigidification, we have prepared a fluorescent irreversible inhibitor as a probe for TG2 activity (RhodB-PGG-K(Acr)-LPF-OH). This probe was synthesized on solid support, characterized kinetically (k(inact) = 0.68 min⁻¹, K(I) = 79 μM), and then used to stain the aorta from rats used as a model of isolated systolic hypertension (ISH). Interestingly, TG2 activity was thus shown to increase over 4 weeks of the hypertension model, corresponding with the previously observed increase in arterial stiffness. These results clearly suggest an association between TG2 and the phenomenon of arterial rigidification.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21035737     DOI: 10.1016/j.chembiol.2010.06.019

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  10 in total

1.  Transglutaminase 2-mediated activation of β-catenin signaling has a critical role in warfarin-induced vascular calcification.

Authors:  Kelly E Beazley; Stephanie Deasey; Florence Lima; Maria V Nurminskaya
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-27       Impact factor: 8.311

Review 2.  The Pressure of Aging.

Authors:  Majd AlGhatrif; Mingyi Wang; Olga V Fedorova; Alexei Y Bagrov; Edward G Lakatta
Journal:  Med Clin North Am       Date:  2017-01       Impact factor: 5.456

Review 3.  Post-translational modifications of tubulin: pathways to functional diversity of microtubules.

Authors:  Yuyu Song; Scott T Brady
Journal:  Trends Cell Biol       Date:  2014-11-25       Impact factor: 20.808

4.  Transglutaminase and polyamination of tubulin: posttranslational modification for stabilizing axonal microtubules.

Authors:  Yuyu Song; Laura L Kirkpatrick; Alexander B Schilling; Donald L Helseth; Nicolas Chabot; Jeffrey W Keillor; Gail V W Johnson; Scott T Brady
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

Review 5.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

6.  Transglutaminase inhibitors attenuate vascular calcification in a preclinical model.

Authors:  Kelly E Beazley; Derek Banyard; Florence Lima; Stephanie C Deasey; Dmitry I Nurminsky; Mikhail Konoplyannikov; Maria V Nurminskaya
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-01       Impact factor: 8.311

7.  Vascular stiffness and increased pulse pressure in the aging cardiovascular system.

Authors:  Jochen Steppan; Viachaslau Barodka; Dan E Berkowitz; Daniel Nyhan
Journal:  Cardiol Res Pract       Date:  2011-08-02       Impact factor: 1.866

Review 8.  Age-associated proinflammatory elastic fiber remodeling in large arteries.

Authors:  Soo Hyuk Kim; Robert E Monticone; Kimberly R McGraw; Mingyi Wang
Journal:  Mech Ageing Dev       Date:  2021-04-08       Impact factor: 5.498

Review 9.  Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo.

Authors:  Thomas M Jeitner; John T Pinto; Arthur J L Cooper
Journal:  Biosci Rep       Date:  2018-09-05       Impact factor: 3.840

10.  Biotechnological applications of transglutaminases.

Authors:  Natalie M Rachel; Joelle N Pelletier
Journal:  Biomolecules       Date:  2013-10-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.